Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Sort descending Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Demylocan Decitabine CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Erbitux Cetuximab Metastatic Colorectal Cancer Do not reimburse Complete Jun 10, 2013 Jan 10, 2014
Erbitux Cetuximab Cancelled
Erivedge Vismodegib Basal Cell Carcinoma Reimburse with clinical criteria and/or conditions Complete Jun 14, 2013 Jan 10, 2014
Erleada Apalutamide metastatic castration-sensitive prostate cancer (mCSPC) Reimburse with clinical criteria and/or conditions Complete Oct 15, 2019 Apr 22, 2020
Erleada Apalutamide non-metastatic castrate resistant prostate cancer (nm-CRPC) Reimburse with clinical criteria and/or conditions Complete Apr 16, 2018 Nov 1, 2018
Faslodex Fulvestrant Locally advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete Jul 17, 2017 Feb 1, 2018
Folotyn Pralatrexate Peripheral T-Cell Lymphoma (PTCL) Reimburse with clinical criteria and/or conditions Complete Jun 1, 2018 Apr 4, 2019
Gazyva Obinutuzumab Follicular Lymphoma Reimburse with clinical criteria and/or conditions Complete Nov 4, 2016 Jun 2, 2017
Gazyva Obinutuzumab Follicular Lymphoma (previously untreated) Do not reimburse Complete Mar 15, 2018 Nov 1, 2018